Keywords: cell, thera, xyotax, sees, strong, ph, iii
Cell Thera's Xyotax sees strong Ph III results
Article | 18 July 2005
US drugmaker Cell Therapeutics posted encouraging gender-specific Phase III results on its anticancer drug candidate Xyotax (paclitaxel poliglumex), at the 11 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
